# In Vitro Evidence for the Efficacy of Manuka Honey and Its Components Against the Major Human Pathogenic Sporothrix Species

**Authors:** Andrea Reis Bernardes-Engemann, Fernando Almeida-Silva, Levi G. Cleare, Jefferson D. da Cruz, Jefferson Rocha de A. Silva, Walter Sotto M. Fernandes Neto, Rosely Maria Zancopé-Oliveira, Ana Claudia Fernandes Amaral, Joshua D. Nosanchuk, Rodrigo Almeida-Paes

PMC · DOI: 10.3390/ph18040534 · Pharmaceuticals · 2025-04-06

## TL;DR

Manuka honey shows antifungal activity against Sporothrix species, which cause sporotrichosis, suggesting it could be a potential alternative treatment.

## Contribution

The study provides in vitro evidence of manuka honey's efficacy against Sporothrix species and identifies potential active components.

## Key findings

- Minimum inhibitory concentrations of manuka honey varied between 5–40% for different Sporothrix species.
- Methylglyoxal alone did not inhibit Sporothrix growth, but manuka honey's activity was reduced by catalase or filtration.
- Chromatography identified 40 volatile organic compounds and two phenolic compounds in manuka honey.

## Abstract

Background/Objectives: While various clinical manifestations occur in sporotrichosis, cutaneous forms predominate. The recommended sporotrichosis treatment is itraconazole, an antifungal with certain restrictions. In recent years, the observation of reduced treatment effectiveness in some patients has arisen, possibly due to Sporothrix spp. resistance mechanisms. Consequently, there is a growing need for alternative therapeutic approaches. This study investigates the antifungal activity of manuka honey (MH) against pathogenic species of the genus Sporothrix. Methods: In this study, we assessed MH antifungal efficacy across concentrations ranging from 5% to 40% against 26 Sporothrix spp. isolates. In addition, its components were evaluated through chromatography and other in vitro techniques. Results: Minimum inhibitory concentrations of MH were found to be 15–40%, 10–15%, and 5–10% for Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa, respectively. Purified methylglyoxal did not hinder Sporothrix growth. The MH antifungal potential was compromised through treatment with catalase or filtration through a 0.22 µm cellulose membrane. Chromatographic analysis of the volatile organic compounds (VOCs) present in MH identified 40 VOCs, including carbonyl compounds, alcohols, esters, aromatic hydrocarbons, heterocyclic compounds, terpenoids, and carboxylic acids. Additionally, two phenolic compounds were identified as potential markers for the authentication of MH, along with a disaccharide that may contribute to its antifungal activity. Conclusions: MH has demonstrated biological activity against the most significant Sporothrix species with pathogenic impact on humans. This suggests its consideration in future research endeavors focused on novel topical treatments for cutaneous sporotrichosis in both human and animal subjects.

## Linked entities

- **Chemicals:** methylglyoxal (PubChem CID 880)
- **Diseases:** sporotrichosis (MONDO:0005968)
- **Species:** Sporothrix brasiliensis (taxon 545650), Sporothrix schenckii (taxon 29908), Sporothrix globosa (taxon 545651)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847]
- **Diseases:** sporotrichosis (MESH:D013174)
- **Species:** Sporothrix brasiliensis (species) [taxon 545650], Sporothrix globosa (species) [taxon 545651], Homo sapiens (human, species) [taxon 9606], Sporothrix schenckii (species) [taxon 29908]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12030384/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12030384/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC12030384/full.md

---
Source: https://tomesphere.com/paper/PMC12030384